抗白三烯药物在咳嗽变异性哮喘中的应用  

Leukotriene receptor antagonist in children cough variant asthma

作　　者：计明红[1] 潘家华[1] 吕勇[1] 

机构地区：[1]安徽省立医院儿科,合肥230001

出　　处：《安徽医学》2009年第7期758-760,共3页Anhui Medical Journal

摘　　要：目的观察孟鲁司特治疗小儿咳嗽变异性哮喘(CVA)的疗效及安全性。方法79例患儿随机分成2组,对照组5岁以下口服氨溴特罗口服溶液,5岁以上口服丙卡特罗片,治疗组在对照组的基础上加用孟鲁司特连服12周。结果治疗组总有效率97.30%,咳嗽复发率5.41%,哮喘转化率8.01%。对照组总有效率64.29%,咳嗽复发率23.81%,哮喘转化率30.95%。两组比较差异均有统计学意义(P<0.05)。结论孟鲁司特治疗小儿咳嗽变异性哮喘有较好疗效,可降低复发率及哮喘转化率,不良反应少。Objective To observe the clinical outcome and safety of Montelukast in the treatment of children cough variant asthma. Methods 79 children with cough variant asthma were randomly divided into treatment group （ n = 37 ） and control group （ n = 42 ） . The controls were treated with Ambrocol hydrochloride and clenbuterol hydrochloride oral solution （ ≤ 5 year - old） and procaterol （ 〉 5 year - old）. The treatment group was treated with Montelukast plus above threrapeutics. The course of Montelukast was 12 weeks. The recurrence rate and the asthma transfomation rate were followed up in half a year after the treatment. Results The total effective rate of the treatment group and control group were 97.30 % and 64.29% （P 〈0. 01 ） . The recurrence rate of which were 5.41% and 23.81% （P 〈0. 01 ） . The asthma transfomation rate of which were 8.01% and 30.95% （ P 〈 0.01 ）. Conclusion Montelukast is an effective agent in the treatment for children cough variant asthma with less side effects ,lower recurrence rate and lower asthma transfomation rate.

关 键 词：孟鲁司特 咳嗽变异性哮喘 小儿 

分 类 号：R725.6[医药卫生—儿科]